Free Delivery Over $100
|
|
|||
|
||||
OverviewTargeting Cell Survival Pathways to Enhance Response to Chemotherapy encompasses recently developed molecular targeting agents and approaches that suppress cell survival signaling. Cell survival signaling attenuates the effectiveness of conventional chemotherapy and numerous mechanisms have been described, and continue to be described, which contribute to cell survival in the face of chemotherapy treatment. Key pathways leading to chemoresistance emanate from growth factor receptors, PI3K, STAT3, anti-apoptotic Bcl-2 family members, autophagy, and the DNA damage response pathway. New advances have underscored the potential of targeting each of these cell survival mechanisms to improve responsiveness to chemotherapy. This book reviews these recent advances and provides a foundational background and hints of new opportunities for basic, translational, and clinical investigators focused on improving therapeutic responses to chemotherapy. Full Product DetailsAuthor: Benjamin Bonavida (Professor, Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine, University of California, USA) , Daniel E. Johnson (Professor, Department of Otolaryngology-Head and Neck Surgery, University of California, San Francisco, USA)Publisher: Elsevier Science Publishing Co Inc Imprint: Academic Press Inc Weight: 0.770kg ISBN: 9780128164327ISBN 10: 0128164328 Pages: 308 Publication Date: 28 March 2018 Audience: Professional and scholarly , Professional & Vocational Format: Hardback Publisher's Status: Active Availability: Manufactured on demand  We will order this item for you from a manufactured on demand supplier. Table of Contents1. Targeting Members of the Epidermal Growth Factor Receptor Family to Improve Response to Chemotherapy2. Targeting the Hepatocyte Growth Factor Receptor to Overcome Resistance to Targeted Therapies3. Roles for AXL and MERTK in Resistance to Cytotoxic and Targeted Therapies4. The JNK Pathway in Drug Resistance5. Fibroblast Growth Factor Receptor (FGFR) Inhibitors: Enhancing Therapeutic Strategies for Solid Tumors6. PIK3CA Mutations in Colorectal and Breast Cancer: Impact on Oncogenesis and Response to Nonsteroidal Anti-inflammatory Drugs7. STAT3 as a Major Contributor to Chemoresistance8. Targeting the Hippo Pathway to Improve Response to Chemotherapy9. Modulation of the Epigenome (Methylome) to Improve Chemotherapeutic Efficacy10. Targeting the ATR Signaling Pathway to Overcome Chemoresistance in Cancer11. PARP Inhibition to Enhance Response to Chemotherapy12. Autophagy Inhibition and Chemosensitization in Cancer Therapy13. Targeting Necroptosis in Anti-Tumor TherapyReviewsAuthor InformationDr Bonavida has vast expertise and various reported publications in the field of tumor cell sensitization to chemotherapy (a total of greater than 500 publications) and in particular the novel role of Nitric Oxide (NO) donors in chemo-sensitization and reversal of drug resistance. In addition, he was the first scientist to co-organize an international meeting on the topic (First International Workshop on NO and Cancer, 2005). Daniel E. Johnson received his undergraduate degrees in chemistry and mathematics from North Park University in Chicago, Illinois. He received his doctoral degree in molecular biology from Princeton University under the mentorship of Dr. Mark A. Bothwell. His postdoctoral research was done under the mentorship of Dr. Lewis T. Williams at the University of California at San Francisco (UCSF). He joined the faculty at the University of Pittsburgh and the University of Pittsburgh Cancer Institute in 1993, where he served as Professor of Medicine and Scientific Director of the Acute Leukemia Working Group. In 2016, he moved to UCSF where he is currently Professor in the Department of Otolaryngology – Head and Neck Surgery. Dr. Johnson has served as a standing member on National Institutes of Health and American Cancer Society study sections and has been a Section Editor for the journal Leukemia since 2001. His research is focused on anti-cancer drug development and the elucidation of cell death and cell survival signaling pathways in head and neck cancer and leukemia. He has additional interests in the development of chemopreventive agents and strategies. Dr. Johnson places particular emphasis on translating laboratory findings to the clinic and has collaborated extensively with physician scientists to initiate and conduct clinical trials in head and neck cancer and acute myeloid leukemia. . Tab Content 6Author Website:Countries AvailableAll regions |
||||
